Chlorion Pharma, Inc. is a privately-held drug discovery company advancing next-generation CNS therapeutics to the clinic.
Currently, Chlorion is focused on the development of small-molecule, disease-modifying compounds for the treatment of neuropathic pain, and subsequently for the treatment of epilepsy, bipolar disease and migraine.
Chlorion's head office and research and development laboratories are located in Quebec City, Canada.
